Zeiss LSM 980 with Airyscan 2 confocal microscope system

项目摘要/摘要 怀特黑德研究所要求60万美元购买急需的蔡司LSM 980 AiryScan 2激光扫描共聚焦显微镜(“Zeiss 980AS2”)，将设在W.M.Keck设施，用于 怀特黑德生物医学研究所(“怀特黑德”)的生物成像(“凯克设施”)。这个 所要求的仪器非常重要，因为它将取代已有9年历史的蔡司LSM 710 NLO(非线性 光学；“Zeiss710”)，这是目前Keck设施中使用最多的显微镜，并提供 变革性的新成像技术，目前在怀特黑德或凯克设施中无法获得。 在过去三年中的每一年，来自25个不同国家的40名研究人员对Zeiss710的平均使用时间为1400小时 实验室。蔡司已通知我们，蔡司710的保修服务将于2022年结束。更换此设备 在此时间之前进行关键的检测对于最大限度地减少由过量 维护问题。我们地区的其他显微镜设施无法容纳大量的 Zeiss710目前支持的使用量，也缺乏关键的新功能 建议的研究项目。蔡司980AS2将为多样化的 本建议书中描述的研究项目，例如启用光学切片以生成高对比度 厚样品中的图像，生成3D数据集，并进行光操纵来分析分子 动力学，如FRAP(光漂白后的荧光恢复)。 至关重要的是，所要求的蔡司980AS2将提供解决以下问题所必需的新尖端技术 美国国立卫生研究院资助的10名研究人员在这项提案中提出了许多悬而未决的问题。Airyscan2 探测器和软件将为凯克设施带来第一批超分辨率能力。32声道 光谱探测器将允许同时成像多达10个荧光团，使研究成为可能 器官和组织中的细胞类型分化。高效率的GaAsP探测器将使成像 使样品变暗，减少活细胞成像过程中的光漂白和光毒性。AiryScan 2 8y 多路复用选项和Z-Piezo Stage可实现极快的图像采集，从而实现更大的样本大小 大容量扫描。控制蔡司980AS2的蔡司禅蓝系统软件将基本上 简化当前艰巨的任务，如多位置瓷砖扫描和查找罕见事件。通过扩展 对于研究人员可用的实验方法和能力，蔡司980AS2将大大增强和 促进NIH资助的许多项目的成功，包括对神经变性、癌症、细菌的分析 细胞分化、代谢调节、细胞分裂和干细胞鉴定。收购蔡司LSM 980和Airyscan2将使研究人员能够解决这些重要的生物医学问题，以及结果 根据NIH的使命，这项研究将包括新的诊断和治疗方法。

Project Summary/Abstract The Whitehead Institute requests $600,000 for the purchase of a critically-needed Zeiss LSM 980 with Airyscan 2 laser scanning confocal microscope (“Zeiss 980AS2”), to be located in the W.M. Keck Facility for Biological Imaging (“Keck Facility”) at the Whitehead Institute for Biomedical Research (“Whitehead”). The instrument requested is of great importance, as it will replace a nine year old Zeiss LSM 710 NLO (non-linear optics; “Zeiss710”) that is currently the most heavily used microscope in the Keck Facility and provide transformative new imaging technologies that are currently unavailable at Whitehead or in the Keck Facility. For each of the past 3 years, the Zeiss710 averaged 1400 hours of use by 40 researchers from 25 different labs. Zeiss has informed us that guaranteed service for the Zeiss710 will end in 2022. Replacement of this critical instrumentation prior to that time is important to minimize interruptions caused by excessive maintenance issues. Other microscopy facilities in our area are unable to accommodate the substantial amount of use the Zeiss710 currently supports, and also lack the critical new capabilities required for the proposed research projects. The Zeiss 980AS2 will provide robust confocal capabilities for the diverse research projects described in this proposal, such as enabling optical sectioning to generate high-contrast images in thick specimens, generating 3D datasets, and conducting photomanipulation to analyze molecular dynamics, such as FRAP (fluorescence recovery after photobleaching). Critically, the requested Zeiss 980AS2 will provide new cutting-edge technologies essential for addressing many outstanding questions from the 10 NIH-funded researchers presented in this proposal. The Airyscan 2 detector and software will bring the first super-resolution capabilities to the Keck Facility. The 32-channel spectral detector will allow simultaneous imaging of up to ten fluorophores, enabling studies that investigate cell type differentiation in organoids and tissues. The high-efficiency GaAsP detectors will enable imaging of dim samples and reduce photobleaching and phototoxicity during live-cell imaging. The Airyscan 2 8Y Multiplex option and Z-piezo stage allow for extremely fast image collection, enabling larger sample sizes for large volume scanning. The Zeiss ZEN Blue System software that controls the Zeiss 980AS2 will substantially simplify currently arduous tasks, such as multi-position tile scanning and finding rare events. By expanding the experimental approaches and capabilities available to researchers, the Zeiss 980AS2 will greatly enhance and facilitate the success of many NIH-funded projects, including the analysis of neural degeneration, cancer, germ cell differentiation, metabolic regulation, cell division, and stem cell identification. Acquisition of the Zeiss LSM 980 with Airyscan 2 will allow researchers to address these important biomedical issues, and the outcomes from this research will include new diagnostics and therapeutics, in accordance with the mission of the NIH.